Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311198 | 0.84 | AOC3 (0.45) | IDO1CNR2AOC3 | |
| SCHEMBL14415638 | 0.79 | TAAR1 (0.51) | TAAR1SLC1A1IDO1AGXT | |
| SCHEMBL14528129 | 0.78 | TAAR1 (0.55) | TAAR1CNR2 | |
| SCHEMBL9883145 | 0.77 | SLC6A2 (0.46) | TAAR1IDO1AOC3 | |
| SCHEMBL19003606 | 0.77 | AOC3 (0.41) | IDO1AOC3 | |
| SCHEMBL23283605 | 0.77 | TAAR1 (0.47) | TAAR1SLC1A1IDO1AGXT | |
| SCHEMBL3884062 | 0.76 | AOC3 (0.40) | IDO1CNR2AOC3 | |
| SCHEMBL10586409 | 0.75 | SLC1A1 (0.49) | TAAR1SLC1A1MEN1KMT2AIDO1 | |
| SCHEMBL31435827 | 0.75 | SLC1A1 (0.49) | TAAR1SLC1A1MEN1KMT2AIDO1 | |
| SCHEMBL18400738 | 0.75 | TAAR1 (0.46) | TAAR1SLC1A1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | TAAR1 1698/4885SLC1A1 181/4885MEN1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.